NM: CSE
Why Novamind?
- Building the infrastructure required for a regulated psychedelics industry
- Rapidly expanding a network of outpatient mental health clinics and research sites
- Provides ketamine-assisted psychotherapy and Spravato™ (esketamine) treatments;
- Ketamine treatment volume grew 90% from 2019 to 2020
- During the same period, total Spravato™ treatments rose 400%
- Positioned to facilitate MDMA and psilocybin therapy post-FDA approval
- Specializing in psychedelic-assisted treatment protocols
- Building centers of excellence for future approved psychedelic treatments
- Approximately CAN$1,900,000 in 2019 revenue
- Strong insider ownership (32.3%)
Yaron Conforti, CEO of Novamind Featured On Cheddar News
Novamind is focused on 3 pillars:
FULL DISCLOSURE: Novamind is an advertising client of AGORA Internet Relations Corp.
Hub On AGORACOM / Corporate Profile
Visited 1 times, 1 visit(s) today
Last modified: July 13, 2026
